Literature DB >> 17875733

PC-1/PrLZ contributes to malignant progression in prostate cancer.

Hui Zhang1, Jian Wang, Bo Pang, Rui-xia Liang, Suping Li, Pei-tang Huang, Ruoxiang Wang, Leland W K Chung, Haiyen E Zhau, Cuifen Huang, Jian-guang Zhou.   

Abstract

PC-1/PrLZ gene overexpression has been identified to be associated with prostate cancer progression. Previous studies have revealed that PC-1 possesses transforming activity and confers malignant phenotypes to mouse NIH3T3 cells. However, the functional relevance of PC-1 expression changes during prostate cancer development and progression remains to be evaluated. In this study, gain-of-function and loss-of-function analyses in LNCaP and C4-2 cells, respectively, were implemented. Experimental data showed that PC-1 expression was in positive correlation with prostate cancer cell growth and anchor-independent colony formation in vitro, as well as tumorigenicity in athymic BALB/c mice. Moreover, PC-1 expression was also found to promote androgen-independent progression and androgen antagonist Casodex resistance in prostate cancer cells. These results indicate that PC-1 contributes to androgen-independent progression and malignant phenotypes in prostate cancer cells. Furthermore, molecular evidence revealed that PC-1 expression stimulated Akt/protein kinase B signaling pathway, which has been implicated to play important roles in promoting androgen refractory progression in prostate cancer. Increased PC-1 levels in C4-2 cells may represent an adaptive response in prostate cancer, mediating androgen-independent growth and malignant progression. Inhibiting PC-1 expression may represent a novel therapeutic strategy to delay prostate cancer progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875733     DOI: 10.1158/0008-5472.CAN-06-4214

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

Review 1.  Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?

Authors:  Jennifer A Byrne; Sarah Frost; Yuyan Chen; Robert K Bright
Journal:  Tumour Biol       Date:  2014-05-06

2.  PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway.

Authors:  Dong Zhang; Dalin He; Yan Xue; Ruoxiang Wang; Kaijie Wu; Hongjun Xie; Jin Zeng; Xinyang Wang; Haiyen E Zhau; Leland W K Chung; Luke S Chang; Lei Li
Journal:  Cancer Res       Date:  2011-03-08       Impact factor: 12.701

3.  Tumor protein D54 is a negative regulator of extracellular matrix-dependent migration and attachment in oral squamous cell carcinoma-derived cell lines.

Authors:  Yoshiki Mukudai; Seiji Kondo; Atsushi Fujita; Yasuto Yoshihama; Tatsuo Shirota; Satoru Shintani
Journal:  Cell Oncol (Dordr)       Date:  2013-03-26       Impact factor: 6.730

4.  MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Authors:  Jennifer A Byrne; Sanaz Maleki; Jayne R Hardy; Brian S Gloss; Rajmohan Murali; James P Scurry; Susan Fanayan; Catherine Emmanuel; Neville F Hacker; Robert L Sutherland; Anna Defazio; Philippa M O'Brien
Journal:  BMC Cancer       Date:  2010-09-17       Impact factor: 4.430

5.  Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.

Authors:  Lei Li; Hongjun Xie; Liang Liang; Ye Gao; Dong Zhang; Leiya Fang; Soo Ok Lee; Jie Luo; Xingfa Chen; Xinyang Wang; Luke S Chang; Shuyuan Yeh; Yuzhuo Wang; Dalin He; Chawnshang Chang
Journal:  Carcinogenesis       Date:  2012-10-26       Impact factor: 4.944

6.  Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.

Authors:  Tom Moritz; Simone Venz; Heike Junker; Sarah Kreuz; Reinhard Walther; Uwe Zimmermann
Journal:  Tumour Biol       Date:  2016-02-05

7.  Tumor protein D52 represents a negative regulator of ATM protein levels.

Authors:  Yuyan Chen; Alvin Kamili; Jayne R Hardy; Guy E Groblewski; Kum Kum Khanna; Jennifer A Byrne
Journal:  Cell Cycle       Date:  2013-08-21       Impact factor: 4.534

8.  PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability.

Authors:  Lan Yu; Zeng-Fu Shang; Jian Wang; Hongtao Wang; Fang Huang; Zhe Zhang; Ying Wang; Jianguang Zhou; Shanhu Li
Journal:  Oncotarget       Date:  2015-08-21

9.  Identification of gene expression signature in estrogen receptor positive breast carcinoma.

Authors:  Arvind D Thakkar; Hemanth Raj; Debarshi Chakrabarti; N Saravanan; Bhaskaran Muthuvelan; Arun Balakrishnan; Muralidhara Padigaru
Journal:  Biomark Cancer       Date:  2010-02-11

10.  Acetylation-dependent regulation of TPD52 isoform 1 modulates chaperone-mediated autophagy in prostate cancer.

Authors:  Yizeng Fan; Tao Hou; Yang Gao; Weichao Dan; Tianjie Liu; Bo Liu; Yule Chen; Hongjun Xie; Zhao Yang; Jiaqi Chen; Jin Zeng; Lei Li
Journal:  Autophagy       Date:  2021-05-26       Impact factor: 13.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.